AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34620676 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 200
Study 34620676 — intervention group
Group type: COMPARATOR
Intervention: Non-ICU patients
Number of subjects: 200
Study 34620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ICU and non-ICU)
Number of subjects: 200
Study 34620702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg every 3 weeks for four treatments)
Number of subjects: 38
Study 34620738 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mean tibiofemoral contact stress (3.3 ± 0.9 MPa)
Number of subjects: 208
Study 34620738 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline peak tibiofemoral contact stress (9.4 ± 4.3 MPa)
Number of subjects: 208
Study 34620767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman layer (BL) inlay transplantation
Number of subjects: 35
Study 34620785 — intervention group
Group type: EXPERIMENTAL
Intervention: Systane iLux thermal pulsation treatment
Number of subjects: 30
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obesity
Number of subjects: 1062
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood pressure/hypertension
Number of subjects: 1062
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic differences in adiposity
Number of subjects: 1062
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure differences by ethnicity
Number of subjects: 1062
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure differences by sex
Number of subjects: 1062
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of elevated blood pressure with BMI increase
Number of subjects: 1062
Study 34620809 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of elevated blood pressure with waist/height ratio increase
Number of subjects: 1062
Study 34621423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-powered ablation guided by ablation index (HPAI) at 40 W on anterior/roof segments and 30 W on posterior/inferior/carina segments
Number of subjects: 118
Study 34621423 — intervention group
Group type: COMPARATOR
Intervention: Conventional-powered ablation guided by ablation index (CPAI) at 30 W on anterior/roof segments and 25 W on posterior/inferior/carina segments
Number of subjects: 118
Study 34621423 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-powered ablation guided by ablation index (HPAI)
Number of subjects: 118
Study 34621423 — intervention group
Group type: COMPARATOR
Intervention: Conventional-powered ablation guided by ablation index (CPAI)
Number of subjects: 118
Study 34621707 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 100 mg twice a day
Number of subjects: 20
Study 34621707 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 200 mg once a day
Number of subjects: 20
Study 34621707 — intervention group
Group type: EXPERIMENTAL
Intervention: YH4808 200 mg twice a day
Number of subjects: 20
Study 34621707 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg twice a day
Number of subjects: 20
Study 34622097 — intervention group
Group type: EXPERIMENTAL
Intervention: GFB-887
Number of subjects: 0
Study 34622097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34622229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 10
Study 34622233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antibody)
Number of subjects: 0
Study 34622233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34622233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 34622445 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 10
Study 34622445 — intervention group
Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 10
Study 34622666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine-rich angiogenic inducer 61 (CCN1)
Number of subjects: 0
Study 34622666 — intervention group
Group type: COMPARATOR
Intervention: GRACE 2.0 risk score
Number of subjects: 0
Study 34622666 — intervention group
Group type: COMPARATOR
Intervention: High-sensitivity Troponin T, hsCRP, NT-proBNP
Number of subjects: 0
Study 34623123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Modified Rankin Scale (MRS) score 0-1 (excellent outcome)
Number of subjects: 297
Study 34623123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who suffered from recurrent ischaemic stroke (RIS) during follow-up
Number of subjects: 297
Study 34623218 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshops (part of pulmonary rehabilitation)
Number of subjects: 201
Study 34623218 — intervention group
Group type: COMPARATOR
Intervention: Location of exercise training (ET) outside the center
Number of subjects: 201
Study 34623313 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost via Breelib nebulizer
Number of subjects: 31
Study 34623313 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study 34623317 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multicomponent mind-body wellness intervention (Peace Power Pack PBC)
Number of subjects: 0
Study 34623489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis group
Number of subjects: 355
Study 34623489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis with severe adenomyosis
Number of subjects: 355
Study 34623583 — intervention group
Group type: COMPARATOR
Intervention: ASD group looking at actor's face during activity
Number of subjects: 132
Study 34623583 — intervention group
Group type: COMPARATOR
Intervention: ASD group looking at moving toy
Number of subjects: 132
Study 34623633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 647
Study 34623633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study 34623633 — intervention group
Group type: COMPARATOR
Intervention: Other glutamate receptor modulators (memantine, cytidine, N-acetylcysteine, riluzole)
Number of subjects: 647
Study 34623637 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg once daily for 14 days
Number of subjects: 10
Study 34623695 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection therapy
Number of subjects: 21
Study 34623939 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychological response after participation in a neuromuscular training and second injury prevention program (responders)
Number of subjects: 66
Study 34623939 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders (those who did not have a meaningful change in psychological response)
Number of subjects: 66
Study 34624252 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks plus apatinib 250 mg once per day
Number of subjects: 20
Study 34624252 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 20
Study 34624250 — intervention group
Group type: EXPERIMENTAL
Intervention: Light restrictions (index <20)
Number of subjects: 20006
Study 34624250 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate lockdowns (20-60)
Number of subjects: 20006
Study 34624250 — intervention group
Group type: EXPERIMENTAL
Intervention: Full lockdowns (>60)
Number of subjects: 20006
Study 34624250 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery beyond 12 weeks from diagnosis
Number of subjects: 20006
Study 34624496 — intervention group
Group type: EXPERIMENTAL
Intervention: Revolution Peripheral Atherectomy System
Number of subjects: 121
Study 34625059 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve stimulation
Number of subjects: 22
Study 34625059 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation (Control)
Number of subjects: 22
Study 34625098 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine exercise regimen
Number of subjects: 0
Study 34625098 — intervention group
Group type: COMPARATOR
Intervention: Upright exercise regimen
Number of subjects: 0
Study 34625120 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation support
Number of subjects: 155
Study 34625120 — intervention group
Group type: COMPARATOR
Intervention: Passive implementation support
Number of subjects: 155
Study 34625214 — intervention group
Group type: EXPERIMENTAL
Intervention: AVH+ group (with auditory-verbal hallucinations)
Number of subjects: 40
Study 34625214 — intervention group
Group type: COMPARATOR
Intervention: AVH- group (without auditory-verbal hallucinations)
Number of subjects: 40
Study 34625424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon-13 MRI
Number of subjects: 0
Study 34625424 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34625791 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab combined with all-trans retinoic acid (ATRA) at a dose of 45 mg/m2
Number of subjects: 50
Study 34625791 — intervention group
Group type: COMPARATOR
Intervention: Daratumumab monotherapy
Number of subjects: 50
Study 34625791 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab combined with ATRA
Number of subjects: 50
Study 34626024 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-1929 photoimmunotherapy (640 mg/m)
Number of subjects: 39
Study 34626169 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of unhealthful plant-based diet index (uPDI)
Number of subjects: 805
Study 34626169 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater adherence to healthful plant-based diet index (hPDI)
Number of subjects: 805
Study 34626169 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater adherence to Fast Food and Sweetened Beverages (FFSB) dietary pattern
Number of subjects: 805
Study 34626169 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall plant-based diet index (oPDI)
Number of subjects: 805
Study 34626318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy
Number of subjects: 6206
Study 34626797 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-I02, a recombinant adeno-associated virus (AAV) serotype 5 vector expressing interferon (IFN)-β, administered as a single intra-articular (IA) injection, dosage not fully specified but mentioned as 0.3 × 10 and 0.6 × 10.
Number of subjects: 12
Study 34627332 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg once daily)
Number of subjects: 360
Study 34627332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 34627340 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg for patients aged ≥6 to <18 years and 2 mg for patients <6 years)
Number of subjects: 40
Study 34627340 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (20 mg for patients weighing <30 kg and 40 mg for patients ≥30 kg)
Number of subjects: 40
Study 34627496 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/XDR assay
Number of subjects: 710
Study 34627593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional TTI-621 (10 mg thrice weekly for 2 weeks)
Number of subjects: 35
Study 34627593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional TTI-621
Number of subjects: 35
Study 34627621 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with obesity undergoing (adeno)tonsillectomy (n=71; 14.9%)
Number of subjects: 4232
Study 34627621 — intervention group
Group type: COMPARATOR
Intervention: Children with obesity (n=365; 77%)
Number of subjects: 4232
Study 34627621 — intervention group
Group type: COMPARATOR
Intervention: Children with obesity (3.7%)
Number of subjects: 4232
Study 34627724 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) drop
Number of subjects: 6544
Study 34628052 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/TIGIT downregulated CAR T cells
Number of subjects: 0
Study 34628052 — intervention group
Group type: COMPARATOR
Intervention: PD-1/TIM-3, PD-1/LAG-3, PD-1/CTLA-4
Number of subjects: 0
Study 34628605 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg IV every 4 weeks
Number of subjects: 1783
Study 34628734 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispectral imaging (MSI)
Number of subjects: 20
Study 34628734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined principal component analysis and k-nearest-neighbor approach
Number of subjects: 20
Study 34629091 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 200
Study 34629091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 34629131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (synthetic tetrahydrocannabinol [THC]), titrated to a dose of 10 mg daily
Number of subjects: 80
Study 34629131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced pluripotent stem cells (iPSCs)
Number of subjects: 0
Study 34629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-based and gene-based therapies using iPSCs
Number of subjects: 0
Study 34629400 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprotection and drug screening opportunities
Number of subjects: 0
Study 34629416 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional mitral regurgitation (FMR) present
Number of subjects: 130
Study 34629416 — intervention group
Group type: EXPERIMENTAL
Intervention: E/e' ≥ 14
Number of subjects: 130
Study 34629416 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (E/e' ≥ 14 with FMR)
Number of subjects: 130
Study 34629416 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (E/e' < 14 without FMR)
Number of subjects: 130
Study 34629416 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (E/e' < 14 with FMR)
Number of subjects: 130
Study 34629425 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured by Patient Health Questionnaire-9
Number of subjects: 157
Study 34629425 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety symptoms measured by Generalized Anxiety Disorder-7
Number of subjects: 157
Study 34629893 — intervention group
Group type: EXPERIMENTAL
Intervention: Iota-Carrageenan nasal spray (4 daily doses for 21 days)
Number of subjects: 394
Study 34629893 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray (4 daily doses for 21 days)
Number of subjects: 394
Study 34630050 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive sensory stimulation inducing cortical 40 Hz gamma oscillation
Number of subjects: 0
Study 34630129 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training for 15 weeks followed by detraining for 5 weeks
Number of subjects: 21
Study 34630129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study 34630163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hypoxemia
Number of subjects: 0
Study 34630163 — intervention group
Group type: COMPARATOR
Intervention: Obstructive sleep apnea
Number of subjects: 0
Study 34630299 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 0
Study 34630406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput, systems serology approach to profile biophysical and functional characteristics of antibodies targeting antigens.
Number of subjects: 0
Study 34630733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) with active tDCS
Number of subjects: 26
Study 34630733 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR) with sham tDCS
Number of subjects: 26
Study 34630780 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad distraction
Number of subjects: 85
Study 34630780 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 85
Study 34631535 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary tumour radiotherapy after targeted therapy
Number of subjects: 27
Study 34631535 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation radiotherapy plan
Number of subjects: 27
Study 34631808 — intervention group
Group type: EXPERIMENTAL
Intervention: New-Onset Atrial Fibrillation
Number of subjects: 0
Study 34631808 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34631809 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs) co-administered with Dual Antiplatelet Therapy
Number of subjects: 0
Study 34631809 — intervention group
Group type: COMPARATOR
Intervention: Dual Antiplatelet Therapy alone
Number of subjects: 0
Study 34631942 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 195
Study 34632308 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin and albendazole
Number of subjects: 0
Study 34632308 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin and albendazole
Number of subjects: 0
Study 34632496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) cases
Number of subjects: 170
Study 34632496 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM cases
Number of subjects: 170
Study 34632876 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus-Sparing Whole-Brain Radiotherapy using Tomotherapy
Number of subjects: 0
Study 34632927 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin A (BoNT-A) injected into brachialis muscle
Number of subjects: 0
Study 34632927 — intervention group
Group type: COMPARATOR
Intervention: Botulinum neurotoxin A (BoNT-A) injected into other elbow flexor muscles (brachioradialis, biceps brachii)
Number of subjects: 0
Study 34632935 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (400 mg once daily) for ≤2 years
Number of subjects: 210
Study 34633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (12.5-200 mg/day during titration, up to 400 mg/day during maintenance)
Number of subjects: 240
Study 34633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (12.5-25 mg/day)
Number of subjects: 240
Study 34633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (50-100 mg/day)
Number of subjects: 240
Study 34633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (maintenance phase)
Number of subjects: 240
Study 34633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (any duration)
Number of subjects: 240
Study 34633084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate (treatment-emergent adverse events)
Number of subjects: 240
Study 34633152 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg ziritaxestat (oral administration)
Number of subjects: 0
Study 34633152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of ziritaxestat
Number of subjects: 0
Study 34633154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g (1 tube) of BF-200 ALA applied on the face (MUsT-1)
Number of subjects: 0
Study 34633154 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g (3 tubes) of BF-200 ALA applied on the face/scalp or body periphery (MUsT-2)
Number of subjects: 0
Study 34633355 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial keratoplasty
Number of subjects: 0
Study 34633355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell injection therapy and tissue-engineered endothelial keratoplasty
Number of subjects: 0
Study 34633355 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet stripping only, Descemet membrane transplantation, and selective endothelial removal
Number of subjects: 0
Study 34633355 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy modalities (antisense oligonucleotides and CRISPR-based gene editing)
Number of subjects: 0
Study 34633357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam HR (Oculus)
Number of subjects: 125
Study 34633357 — intervention group
Group type: COMPARATOR
Intervention: Casia 2 (Tomey)
Number of subjects: 125
Study 34633441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipstick test
Number of subjects: 300
Study 34633441 — intervention group
Group type: EXPERIMENTAL
Intervention: Utriplex test
Number of subjects: 300
Study 34633441 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidbac test
Number of subjects: 300
Study 34633441 — intervention group
Group type: EXPERIMENTAL
Intervention: Uriscreen test
Number of subjects: 300
Study 34633450 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour plasma glucose (2hPG) after a 75-g oral glucose challenge
Number of subjects: 830
Study 34633450 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 830
Study 34633450 — intervention group
Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG) and 2-hour plasma glucose (2hPG)
Number of subjects: 830
Study 34633450 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour plasma glucose (2hPG)
Number of subjects: 830
Study 34633449 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 30
Study 34633449 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG relative power in beta and high beta bands
Number of subjects: 30
Study 34633449 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG relative power at delta and theta bands
Number of subjects: 30
Study 34633513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MPFL reconstruction
Number of subjects: 213
Study 34633513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MPFL reconstruction by surgeons with a routine of more than ten procedures
Number of subjects: 213
Study 34634050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fermentable oligo-, di-, monosaccharide and polyol (FODMAP) diet (LFD)
Number of subjects: 53
Study 34634050 — intervention group
Group type: COMPARATOR
Intervention: Traditional IBS diet (TID)
Number of subjects: 53
Study 34634070 — intervention group
Group type: EXPERIMENTAL
Intervention: Belun Sleep Platform (BSP)
Number of subjects: 78
Study 34634070 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm combining STOP-Bang cutoff of 5 and bAHI cutoff of 15 events/h
Number of subjects: 78
Study 34634256 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg, 600 mg, or 800 mg once daily for 10 days per cycle with dose-adjusted EPOCH-R (one cycle every 3 weeks)
Number of subjects: 30